Technical And Clinical Validation Of Somatic Cnv Detection From Circulating Tumor Dna.
Kaican Cai,Zisong Zhou,Di Lu,Kejun Nan,Xiaochen Zhao,Yuejun Chen,Dadong Zhang,Hua Dong,Fu-Gen Li,Yu Yao
DOI: https://doi.org/10.1200/JCO.2018.36.15_suppl.e21055
IF: 45.3
2018-01-01
Journal of Clinical Oncology
Abstract:e21055 Background: While methods for detecting SNV and indel in circulating tumor DNA (ctDNA) with hybrid-capture based next generation sequencing (NGS) has been available, algorithm for calling copy number variation(CNV) is more challenging. Here we present a method enabling CNV detection in very low amount of ctDNA with high sensitivity and specificity. Methods: First of all, we built a background model with a customized 150 gene panel cfDNA sequencing data from 10 healthy people. This model was then applied to normalize read depth to further reduce background noise. The probe level log2ratio was segmented using circular binary segmentation. Segments with log2ratio above 3 fold standard deviation was treated as amplification. Then we used NCI-H1573 and HCC1954 cell culture supernatant, which harbored three CNVs: ERBB2 (HCC1954), EGFR and MET (NCI-H1573), to mimic human ctDNA. Both in-silicon and in-vitro simulations were performed to define the detection limit. We validated the CNV concordance of FFPE samples and matched controls with WES profiling and plasma samples with 150 gene panel profiling from 28 lung cancer patients. Additional 1495 ctDNA samples were also profiled with 150 gene panel. Results: For in-silicon spike-in, the detection limit of ctDNA fraction is about 0.3% for ERBB2 (2.2 copy), 5% for MET (2.5 copy), 1% for EGFR (2.2 copy). For in-vitro spike-in, the detection limit of ctDNA fraction is about 1% for ERBB2 (2.6 copy), 5% for MET (2.5 copy), 3% for EGFR (2.6 copy). Compared with WES CNV results, the specificity of CNV calling from ctDNA panel is 95.5% and sensitivity is 50% when copy number > 6, and 71.4% when copy number > 12. We profiled 1495 lung cancer ctDNA samples with 150 gene panel and detected 15 HER2 amplification(1%), 75 EGFR amplification(5%) and 30 MET amplification samples(2%). An advanced lung adenocarcinoma patient with acquired resistance after EGFR TKI treatment, MET amplification was detected in plasma ctDNA. Patient accepted crizotinib and reached partial response. Conclusions: We developed a pipeline to detect CNV in very low amount of ctDNA with high sensitivity and specificity, which improves the accuracy of CNV calling in noninvasive way and avoids unnecessary biopsy on tumor patients.